External news of interest
Not surprisingly, news about Neuroendocrine Cancer has been a bit slow but I sense that things are starting to pick up. Here’s a few items I picked up during July from my google alerts or from twitter (a key source for me to hear about what’s happening).
1. 64Cu DOTATATE PET scans. This is an alternative scan that’s been in use in Europe but is undergoing trials in US – it has some advantages in particular a more logistically efficient generator system than the Ga68 PET. There’s been an announcement of an expanded access program in US providing access to nuclear PET scans for NET patients including those not yet formally diagnosed but who are suspicious for NETs. Read more by clicking here.
2. Long term NET study. This sounds like an amazing study designed to generate more understanding of the disease which may help others in the future. There’s limited placed and the contact details can be found in this Facebook post.
3, XERMELO (Telotristat Ethyl) has new owners. “In a move that Lexicon Pharmaceuticals Inc. chief Lonnel Coats said will focus the company on its phase II neuropathic pain program, The Woodlands, Texas-based venture has agreed to sell one of its two approved products, the carcinoid syndrome diarrhea therapy Xermelo (telotristat ethyl), to Tersera Therapeutics LLC”. I don’t expect this to make any difference to the drug or its supply – business as usual. The outer package may change to reflect new owners but the brand name XERMELO will most likely be part of the sale. Read more by clicking here.
4. Update on the Uppsala virus trial (AdVince). After 2 years of silence, an update on the Uppsala Oncolytic Virus trial. The candidate drug called AdVince has so far been tested in six patients in Sweden by Prof Essand, who is one of the two largest shareholders in Elicera. The company has now opened a second clinical site in Tubingen in Germany and is gearing up for a trial of 12 patients. However, this remains a crowdfunding campaign. I mention this not because I’m suggesting a donation, but because it’s not the normal way clinical trials are funded. Read more by clicking here.
Coping with lockdown
During July, I was quite active both on my website and looking after myself. It’s important in these times to keep active and not let everything get on top of you. We all have different ways of dealing with this and I hope some of you have found solace or advice in my private group or even just reading my various blog posts or on my public Facebook sites. I still see myself as someone at risk, but there are other risks at play here – mental health can be as important as physical health in times of stress and anxiety. Back in March I told the story of my own symptomatic period and perhaps one day I might find out if I have antibodies when I’m tested accordingly. You can read this COVID-19 diary by clicking here. I also continued my diary until the middle of July with 12 episodes which were very popular when published on my public Facebook page. You can read Episode 12 by clicking here and it contains links to Episodes 1 through to 11. It might also give you some holiday or daytrip ideas if you’re planning!
And of course not forgetting my 10 year ‘cancerversary’ of my diagnosis on 26th July. I can tell you now I had no idea I might make this date and it took me a few years before I had the confidence to think it was possible.
Despite some fairly big relaxations to the UK lockdown rules, I have not changed my cautionary approach too much, still staying away from towns and shopping – although I’m gradually reintroducing to some locations where I feel safe. However, it’s great that our family can now visit us at home providing we practice good social distancing. We’ve since had a few visits and vice versa.
We are now in serious holiday mode but local days out plus a few days here and there. We are booked to visit Cambridgeshire and the Yorkshire in August, two separate trips. I will post some stories about these adventures as normal on my public Facebook page.
- Early in the lockdown, I was interviewed over the telephone by a Pharma company after writing an article about their product currently in clinical trials. This was a surprise call but was happy to help. You can read the interview above in one of the posts released in June or just click here.
- I made some short patient videos about coping with living under COVID-19. If they get published, I’m sure you’ll get to see it. Stay tuned.
- I took part in a podcast interview for a US based patient support site – awaiting publication. Stay tuned.
- I’ve been invited to take part in an online NET conference organised by the Middle East NET Society (MENETS). This is a virtual online event where the speakers will be well known NET Specialists and patients. I think my talk is centred around “Patient Orientation”. MENETS is in the process of validating schedules and will be ready to publish the initial agenda by the end of July 2020. In the meantime, you can save the date – click here for more details. Very grateful to my friend Mike Rosenberg for inviting me to speak and for adding my website alongside other illustrious organisations/individuals on the MENETS website.
July Blog Activity
I was quite busy pushing out new stuff, partly trying to get things back to normal. You can see a sample of some of the July posts below – take a look, each one has its own share button to various social media platforms. Share with others please.
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability
I see a lot of emotional and anxiety issues in my private group. I guess cancer diagnoses are involved in much of it adding to
Opinion Post I’ve lost count of the number of diet related questions I receive online or are posted in my private Facebook support group. The
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) – (COMPOSE)
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) – (COMPOSE) is a new trial commencing September
New Clinical Trial – Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
When I see a trial for Gastroenteropancreatic NETs (GEPNETs), I know that BP (Bronchopulmonary) NETs (includes Lung) are not included. When you look at the
Neuroendocrine Tumors: Targeted Therapies – Update from NET Specialist Diane Reidy-Lagunes, MD, Memorial Sloan-Kettering Cancer Center – August 2021
Background. For those who want a quick run through of Neuroendocrine Tumors from diagnosis to selection of treatment, about the treatments themselves plus what is
OPINION. FOR UK NEUROENDOCRINE CANCER PATIENTS (probably applies to all cancer patients in practice). Some of my findings are potentially applicable in other countries. Nothing
Small Intestine Neuroendocrine Tumours (SI NET) are one of the most common types of Neuroendocrine Cancer, and also one of the most challenging to diagnose
In my patient support group of 6000+, fatigue is very commonly discussed, and it certainly gets bags of empathy from the readers. I remember being
Website and Social Media updates
Website. Some of you will also have noticed a change in the layout of my website to include more menus for easier navigation and more sharing buttons to help you share what you like and find useful for others. Thanks if you’re using them already. If you wanted to practice, you’ll see them at the top and bottom of this newsletter – share away!
Twitter. I’m quieter on twitter which is currently quite depressing – I hadn’t realised how many trolls there on that medium but I guess many people remain frustrated by COVID-19 and many other political issues. Still sharing my twitter newsletters though – sign up here.
Email Newsletters. I’m still learning how to release newsletters like this one plus other ad hoc stuff, I should have that in place by the next monthly iteration – look out for a new email template, then you’ll know! You can sign up for these newsletters in the form elsewhere in the side or bottom of the post – it takes around 5 seconds!
Private Facebook Group
You can join here, open to patients and their primary caregivers/carers/supporters.
Neuroendocrine Cancer Definitions. I continue to work on my A to Z facility and making progress – I now have a structure with many definitions already linked to at least one blog post. It’s quite usable if you just wanted to find an article containing a particular term. I’m currently getting rid of unwanted terms and updating new ones to link to my website. Try it out, you might be surprised how useful it is despite its ‘in construction’ condition. In the database, click a term and it will currently take you to the posts containing that ‘tag’ and where I’ve populated so far, a short explanation. The A to Z of Neuroendocrine Cancer
Thanks for all your support in July 2020, it’s really much appreciated.
Looking forward to a much safer July. Go on, try the share button!